Ambagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagon says its approach opens up novel target space as well as having an innovative mechanism of action.
Protein–protein interactions (PPIs) are one of the core processes by which cells function and interact with their environment, making them very interesting targets for modulation by small molecules. There is significant ongoing development of PPI inhibition as a therapeutic strategy. However, Ambagon is taking a new approach and applying its expertise towards PPI stabilization.
Ambagon is initially focused on discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches.
Initially focused on breast cancer, Ambagon says it’s platform approach will also open opportunities to address other major unmet clinical needs.
Subscribe for alerts on new companies featured on Startups.Bio
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® …